New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer

Auteurs-es

  • Ricardo A. Rendon Department of Urology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS

DOI :

https://doi.org/10.5489/cuaj.69

Résumé

Renal cell carcinoma is the most lethal urologic malignancy. Up to 30% of patients with kidney cancer have metastatic disease and 30% of those treatedfor local or locally advanced disease will progress to metastases. Radical nephrectomy is the standard treatment for the management of nondisseminated kidney cancer, but the role of cytoreductive nephrectomy for patients with metastatic disease is controversial. In this paper, the rationale for cytoreductivenephrectomy is described and the currently available evidence for andagainst it is evaluated. The different approaches to defining prognostic factorsto select which patients will benefit from cytoreductive nephrectomy willalso be described. Finally, the role of cytoreductive nephrectomy in the eraof new targeted therapies is discussed.

Téléchargements

Les données relatives au téléchargement ne sont pas encore disponibles.

Téléchargements

Publié-e

2012-12-11

Comment citer

Rendon, R. A. (2012). New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer. Canadian Urological Association Journal, 1(2S). https://doi.org/10.5489/cuaj.69